ad image

Articles
Expert Interviews
Roundtable
Press Releases
Videos

Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing

Company Info

Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us
Nice Insight
That's Nice

Reach Our Team

Contact Us
Advertise

My Account

Login/Sign up

Site

Privacy Policy
Terms And Conditions

© 2024 PHARMA’S ALMANAC. All rights reserved.

Headquarters

290 Concord Road
Billerica, MA 01821

Visit the Website

MilliporeSigma

CDMO

Overview

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. Merck KGaA, Darmstadt, Germany holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

50 Contributors1 / 3

1 / 3

58 Contributions1 / 3

1 / 3

Lars Albermann, Ph.D.

Lars Albermann, Ph.D.

Head of Pharma Registration and Regulatory Projects

Janmeet Anant

Janmeet Anant

Senior Regulatory Consultant

Estelle Beguin Ph.D.

Estelle Beguin Ph.D.

Strategic Marketing Manager - Synthetic Lipids, mRNA Value Chain | Life Science Services

Aniruddha Bose

Aniruddha Bose

Bioprocess Automation Consultant

Melanie Brandl, Ph.D.

Melanie Brandl, Ph.D.

Senior Global Manager CHO Catalog Media, Life Science, BioProcessing

Thomas Briel, Ph.D.

Thomas Briel, Ph.D.

Strategic Marketing Manager – Excipients Liquid Application, SAFC® Raw Materials

Moritz Beck-Broichsitter, Ph.D.

Moritz Beck-Broichsitter, Ph.D.

Associate Director, Formulation Service

Andrew Bulpin, Ph.D.

Andrew Bulpin, Ph.D.

Head of Process Solutions Strategic, Marketing and Innovation

Monica Cardona

Monica Cardona

Global Senior Marketing Manager

Youness Cherradi, Ph.D.

Youness Cherradi, Ph.D.

Senior Process Development Scientist, Technology Management

Nargisse El-Hajjami, Ph.D.

Nargisse El-Hajjami, Ph.D.

Associate Director, Senior Consultant, Novel Modalities (EMEA), Strategy Operationalization

Nelli Erwin, Ph.D.

Nelli Erwin, Ph.D.

Liquid Formulation R&D, Senior Manager Protein Stability

David Goeddel, Ph.D.

David Goeddel, Ph.D.

Director of API R&D

Elizabeth Goodrich

Elizabeth Goodrich

Head of Process Technology, BioContinuum™ R&D

Elina Gousseinov

Elina Gousseinov

Senior Process Development Scientist

Alana Gouveia

Alana Gouveia

Protein Formulation Scientist & Global Lead of the Feasibility Testing Service, SAFC® Raw Materials

Markus Greulich

Markus Greulich

Strategic Marketing Manager – Excipients Liquid Application

Balu Guduri

Balu Guduri

Strategic Marketing Manager of Excipients for Formulation Franchise

Meeta Gulyani

Meeta Gulyani

Head of Strategy, Business Developments, and Sustainability

Matt Hanson

Matt Hanson

Head of API Franchise

Exploring New Possibilities with 3D Printing of Pharmaceuticals

3D Printing

Exploring New Possibilities with 3D Printing of Pharmaceuticals

Thomas Kipping, Ph.D.

MilliporeSigma

PAO-02-24-CL-11Feb 23, 2024

Viscosity Reduction with An Excipient Platform and Feasibility Testing Service

Viscosity Reduction

Viscosity Reduction with An Excipient Platform and Feasibility Testing Service

Alana Gouveia

MilliporeSigma

PAO-08-23-CL-03Aug 10, 2023

Preparing Today for a Potential Ban on Titanium Dioxide in Pharmaceutical Drug Products

Alternative Excipient

Preparing Today for a Potential Ban on Titanium Dioxide in Pharmaceutical Drug Products

Almut von der Brelie

MilliporeSigma

PAO-08-23-CL-01Aug 03, 2023

Enhanced Solubility through API Processing: Salt and Cocrystal Formation

API

Enhanced Solubility through API Processing: Salt and Cocrystal Formation

Thomas Briel, Ph.D.; David Luedeker, Ph.D.

MilliporeSigma

PAO-05-23-CL-04May 05, 2023

Advancing Extrusion-Based 3D Printing for Drug Production

3D Printing

Advancing Extrusion-Based 3D Printing for Drug Production

Thomas Kipping, Ph.D.; Xianghao Zuo, Ph.D.

MilliporeSigma

PAO-11-022-CL-14Nov 29, 2022

High-Intensity Sweeteners for Taste Optimization

Sweeteners

High-Intensity Sweeteners for Taste Optimization

Almut von der Brelie

MilliporeSigma

PAO-11-022-CL-12Nov 28, 2022

Raman Spectroscopy as a PAT Tool Advancing Biopharma Manufacturing

Real-Time Monitoring

Raman Spectroscopy as a PAT Tool Advancing Biopharma Manufacturing

Stacy Shollenberger

MilliporeSigma

PAO-09-022-CL-08Sep 30, 2022

Manufacturing Investment

MilliporeSigma Announces Investment of More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, France

MilliporeSigma

PR-M09-22-02Sep 08, 2022

Regulatory Considerations for Lipid Excipients

Lipid Excipients

Regulatory Considerations for Lipid Excipients

Claudia Widmann; Estelle Beguin Ph.D.

MilliporeSigma

PAO-07-022-CL-04Aug 15, 2022

Assuring Excipient Quality for Parenteral Products

Excipient Quality Assurance

Assuring Excipient Quality for Parenteral Products

Lars Albermann, Ph.D.; Markus Greulich

MilliporeSigma

PA287Jul 28, 2022

Optimizing Fed-Batch Processes with Chemically Defined Media and Feeds

Biomanufacturing

Optimizing Fed-Batch Processes with Chemically Defined Media and Feeds

Jonathan Kaiser

MilliporeSigma

PAO-07-022-CL-02Jul 11, 2022

How the Developability Classification System and Advanced Excipients Enable the Formulation of Poorly Soluble APIs

Advanced Excipients

How the Developability Classification System and Advanced Excipients Enable the Formulation of Poorly Soluble APIs

Daniel Joseph Price, Ph.D.

MilliporeSigma

PAO-04-022-CL-07Apr 27, 2022

Better Bioprocessing Efficiency Through Centralized Orchestration

Bioprocessing

Better Bioprocessing Efficiency Through Centralized Orchestration

Aniruddha Bose

MilliporeSigma

PAO-03-022-CL-23Mar 29, 2022

Enabling Stable, High-Viscosity Injectable Drug Products with New Excipient Combinations

Excipients

Enabling Stable, High-Viscosity Injectable Drug Products with New Excipient Combinations

Tobias Rosenkranz, Ph.D.; Sara Kalman

MilliporeSigma

PAO-01-22-CL-02Mar 12, 2022

Facility Acquisition

MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-Up

MilliporeSigma

PR-M02-22-20Feb 23, 2022

Business Development

MilliporeSigma Announces Organizational Transformation to Strengthen CDMO Offering and Accelerate Future Growth

MilliporeSigma

PR-M02-22-03Feb 07, 2022

Improving the Handling and Safety of Pharmaceutical Raw Materials Through Dry Granulation

Improving the Handling and Safety of Pharmaceutical Raw Materials Through Dry Granulation

Thomas Briel, Ph.D.; Moritz Beck-Broichsitter, Ph.D.

MilliporeSigma

PA141Jan 28, 2022

Boosting Cell Densities and Productivity with Tailored Media in Seed Train

Biomanufacturing

Boosting Cell Densities and Productivity with Tailored Media in Seed Train

Melanie Brandl, Ph.D.

MilliporeSigma

PAO-11-21-CL-17Dec 03, 2021

Accelerating Biologics Development with High-Quality Protein Stabilization Excipients

Formulation

Accelerating Biologics Development with High-Quality Protein Stabilization Excipients

Balu Guduri; Nelli Erwin, Ph.D.

MilliporeSigma

PAO-11-21-CL-12Nov 18, 2021

Pandemic Playbook for Gene Therapy Manufacturing

Gene Therapy

Pandemic Playbook for Gene Therapy Manufacturing

Ratish Krishnan; David Loong, Ph.D.; Nargisse El-Hajjami, Ph.D.

MilliporeSigma

PAO-09-21-CL-14Sep 29, 2021